texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Share:

 
 

Carlos A. Encarnación, M.D., FACP

Carlos A. Encarnación, M.D., FACP Photo

Provider Type: Physician

Specialties:
Board Certifications:
  • Internal Medicine
  • Medical Oncology

Downloads

General Summary

Dr. Encarnación serves as Site Research Leader and Area Medical Director for the Waco locations of Texas Oncology. His current focus is clinical genetics and management of high-risk patients, for which he participates in the US Oncology Network/Texas Oncology Genetic Risk Evaluation and Treatment program. He is also a member of the Texas Oncology Board of Directors and chaired multiple committees at local hospitals.

Education

  • Fellowship in Medical Oncology
    The University of Texas Health Science Center, San Antonio, TX
  • Residency in Internal Medicine, Chief Resident
    Veterans Administration Hospital, San Juan, Puerto Rico
  • Internship in Internal Medicine
    Veterans Administration Hospital, San Juan, Puerto Rico
  • Medical Doctorate
    University of Puerto Rico School of Medicine, San Juan, Puerto Rico
  • Intensive Program in Cancer Risk Assessment and Genetics
    City of Hope National Medical Center, CA

Accolades & Memberships

  • Alpha-Omega-Alpha Honor Medical Society
  • American Cancer Society Fellowship Grant
  • American College of Physicians
  • American Society of Clinical Oncology
  • Ciba-Geigy Fellowship Grant
  • Fellow of the American College of Physicians
  • Fellow, American College of Physicians
  • Friend of the ACS Award
  • Katherine Wood Johnson Travel Award
  • McLennan County Medical Society
  • National Community Oncology Dispensing Association
  • Scientific Research Award, ACP Puerto Rico Chapter
  • Texas Medical Association
  • University of Puerto Rico School of Medicine Certificate of Merit
  • Upjohn Travel Award

Why a patient should choose treatment at your practice?

At Texas Oncology, we offer a personalized, leading edge treatment program for our patients including genetic counseling and participation in clinical trials while staying close to home and with a personal approach. Our patients are valuable individuals, not numbers. Our staff is skilled, compassionate, highly trained, and have many years of experience in their fields.

What is your personal philosophy around patient care?

Respect. I will always respect a patient’s decision. I believe that patients are intelligent and are fully able to make decisions if they are given the proper information. Also, I truly believe in quality of life and will bring up issues of terminal care when necessary.

Publications

  • High Risk Breast Cancer Genes at 8q22-24 and Their Role in Over 5000 Patients Evaluated With the 70-Gene Recurrence Assay

    Journal of Clinical Oncology, 2020

  • A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Urothelial Cancer

    Journal of Clinical Oncology, 2019

  • A Phase 1b/2 Trial of Lenvatinib in Combination With Pembrolizumab in Patients With Non-Small Cell Lung Cancer

    Journal of Clinical Oncology, 2018

  • Phase II Evaluation of Nanoparticle Albumin Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

    Journal of Clinical Oncology, 2009

  • Results of a Phase II Open-Label, Nonrandomized Trial of Oral Satraplatin in Patients With Metastatic Breast Cancer

    Breast Cancer Research and Treatment, 2009

Show all Publications
  • Results of a Phase II Evaluation of Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

    ASCO Proceedings, 2007

  • Results of a Phase II Open-Label Study of Capecitabine in Combination With Irinotecan As First-Line Treatment for Metastatic Colorectal Cancer

    Clinical Colorectal Cancer, 2005

  • A Phase II Open-Label Study of Capecitabine in Combination With Irinotecan As First-Line Treatment for Metastatic Colorectal Cancer

    ASCO Proceedings, 2004

  • Preliminary Toxicity Results From a Phase II Open-Label, Multicenter Study of Capecitabine in Combination With Irinotecan As First-Line Treatment for Metastatic Colorectal Cancer

    ASCO Proceedings, 2003

  • Expression of Estrogen (ER) and Progesterone Receptors (PgR) in Breast Cancer Biopsies in Patients With Tamoxifen Resistance

    ASCO Proceedings, 1993

  • Development of an Enhanced Hormonal Response After Estrogen Withdrawal in MCF-7 Tumors

    AACR Proceedings, 1993

  • Measurement of Steroid Hormone Receptors in Breast Cancer Patients on Tamoxifen

    Breast Cancer Research and Treatment, 1993

  • Effects of the Pure Steroidal Antiestrogen ICI 182780 on Growth of MCF-7 Tumors in Nude Mice

    Breast Cancer Research and Treatment, 1993

  • Durable Complete Remission in a Patient With Refractory Mediastinal Non-Seminomatous Germ Cell Tumor After Tandem High-Dose Chemotherapy and Autologous Bone Marrow Transplantation

    Bone Marrow Transplantation, 1993

  • Steroid Hormone Receptors. Basic and Clinical Aspects

    Estrogen Receptor Variants in Breast Cancer, 1993

  • Mammary Tumorigenesis and Malignant Progression

    Estrogen Receptor Variants in Breast Cancer, 1993

  • Hormone Withdrawal May Enhance Estrogen Sensitivity in Breast Cancer Cells

    Breast Cancer Research and Treatment, 1992

  • Anomalous Drainage of the Common Bile Duct: Demonstration by Hepatobiliary Imaging

    Am J Roentgenology, 1987

Research Interest

Breast cancer and cancer genetics

Medical Practice

  • Waco Hematology, Oncology, Endocrinology Associates (1993 – 1996)

Other Information

Dr. Encarnación is married, and enjoys reading, traveling, eating out, beekeeping, and playing guitar.